JP2021080300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021080300A5 JP2021080300A5 JP2021036318A JP2021036318A JP2021080300A5 JP 2021080300 A5 JP2021080300 A5 JP 2021080300A5 JP 2021036318 A JP2021036318 A JP 2021036318A JP 2021036318 A JP2021036318 A JP 2021036318A JP 2021080300 A5 JP2021080300 A5 JP 2021080300A5
- Authority
- JP
- Japan
- Prior art keywords
- agitation
- combination
- quinidine
- dextromethorphan
- aggression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 136
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical class C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 68
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 68
- 229960001404 quinidine Drugs 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 36
- 238000013019 agitation Methods 0.000 claims description 32
- 230000016571 aggressive behavior Effects 0.000 claims description 22
- 206010012289 Dementia Diseases 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 206010022998 Irritability Diseases 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 230000006399 behavior Effects 0.000 claims description 8
- 239000000902 placebo Substances 0.000 claims description 7
- 229940068196 placebo Drugs 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010013142 Disinhibition Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims 8
- 229960001985 dextromethorphan Drugs 0.000 description 47
- 238000000034 method Methods 0.000 description 36
- 239000002552 dosage form Substances 0.000 description 31
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 28
- 229960004482 quinidine sulfate Drugs 0.000 description 28
- -1 dextromethorphan compound Chemical class 0.000 description 25
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 12
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 12
- 206010001497 Agitation Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 5
- 239000004381 Choline salt Chemical class 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
- 239000007983 Tris buffer Chemical class 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 4
- 235000019417 choline salt Nutrition 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 239000012458 free base Chemical class 0.000 description 4
- 229910003002 lithium salt Inorganic materials 0.000 description 4
- 159000000002 lithium salts Chemical class 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 4
- 150000003248 quinolines Chemical class 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023096152A JP2023105265A (ja) | 2014-09-14 | 2023-06-12 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Applications Claiming Priority (35)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050170P | 2014-09-14 | 2014-09-14 | |
| US62/050,170 | 2014-09-14 | ||
| US201462061451P | 2014-10-08 | 2014-10-08 | |
| US62/061,451 | 2014-10-08 | ||
| US201462063122P | 2014-10-13 | 2014-10-13 | |
| US62/063,122 | 2014-10-13 | ||
| US201462063861P | 2014-10-14 | 2014-10-14 | |
| US62/063,861 | 2014-10-14 | ||
| US201462068742P | 2014-10-26 | 2014-10-26 | |
| US62/068,742 | 2014-10-26 | ||
| US201562111053P | 2015-02-02 | 2015-02-02 | |
| US62/111,053 | 2015-02-02 | ||
| US201562111590P | 2015-02-03 | 2015-02-03 | |
| US62/111,590 | 2015-02-03 | ||
| US201562128446P | 2015-03-04 | 2015-03-04 | |
| US62/128,446 | 2015-03-04 | ||
| US201562162140P | 2015-05-15 | 2015-05-15 | |
| US62/162,140 | 2015-05-15 | ||
| US201562165535P | 2015-05-22 | 2015-05-22 | |
| US62/165,535 | 2015-05-22 | ||
| US201562169997P | 2015-06-02 | 2015-06-02 | |
| US62/169,997 | 2015-06-02 | ||
| US201562180026P | 2015-06-15 | 2015-06-15 | |
| US62/180,026 | 2015-06-15 | ||
| US201562193347P | 2015-07-16 | 2015-07-16 | |
| US62/193,347 | 2015-07-16 | ||
| US201562205061P | 2015-08-14 | 2015-08-14 | |
| US62/205,061 | 2015-08-14 | ||
| US201562216636P | 2015-09-10 | 2015-09-10 | |
| US62/216,636 | 2015-09-10 | ||
| US201562217142P | 2015-09-11 | 2015-09-11 | |
| US201562217470P | 2015-09-11 | 2015-09-11 | |
| US62/217,470 | 2015-09-11 | ||
| US62/217,142 | 2015-09-11 | ||
| JP2019201410A JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019201410A Division JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096152A Division JP2023105265A (ja) | 2014-09-14 | 2023-06-12 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021080300A JP2021080300A (ja) | 2021-05-27 |
| JP2021080300A5 true JP2021080300A5 (https=) | 2022-08-17 |
| JP7360409B2 JP7360409B2 (ja) | 2023-10-12 |
Family
ID=55459653
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533726A Pending JP2017531033A (ja) | 2014-09-14 | 2015-09-14 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2019201410A Withdrawn JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2021036318A Active JP7360409B2 (ja) | 2014-09-14 | 2021-03-08 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2023096152A Pending JP2023105265A (ja) | 2014-09-14 | 2023-06-12 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533726A Pending JP2017531033A (ja) | 2014-09-14 | 2015-09-14 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
| JP2019201410A Withdrawn JP2020019818A (ja) | 2014-09-14 | 2019-11-06 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023096152A Pending JP2023105265A (ja) | 2014-09-14 | 2023-06-12 | 認知症における激越の処置のためのデキストロメトルファン化合物およびキニジンを含む医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190111047A1 (https=) |
| EP (4) | EP3193872A4 (https=) |
| JP (4) | JP2017531033A (https=) |
| KR (1) | KR20170052684A (https=) |
| CN (3) | CN117427077A (https=) |
| AU (3) | AU2015314710A1 (https=) |
| CA (1) | CA2960031A1 (https=) |
| IL (2) | IL250786A0 (https=) |
| MX (3) | MX2017003066A (https=) |
| MY (1) | MY198587A (https=) |
| PH (1) | PH12017500444A1 (https=) |
| RU (1) | RU2017112747A (https=) |
| SG (2) | SG11201701645WA (https=) |
| TW (3) | TW202106301A (https=) |
| WO (1) | WO2016040930A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2357183B1 (en) | 2007-05-01 | 2015-07-01 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| WO2017020002A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| ES2925277T3 (es) * | 2016-07-04 | 2022-10-14 | Avanir Pharmaceuticals Inc | Métodos para la síntesis de dextrometorfano deuterado |
| CN110831584B (zh) * | 2017-05-04 | 2023-03-10 | 埃克塞瓦有限责任公司 | 具有新颖的组合物、组合的靶向药物拯救及其方法 |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| AU2019269739B2 (en) | 2018-05-18 | 2025-12-18 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| SMT202600055T1 (it) * | 2019-01-07 | 2026-03-09 | Antecip Bioventures Ii Llc | Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici |
| AU2020241611A1 (en) * | 2019-03-18 | 2021-11-04 | Avanir Pharmaceuticals, Inc. | Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine |
| US20230270738A1 (en) * | 2020-04-27 | 2023-08-31 | Avanir Phrmaceuticals Inc. | Methods of treating agitation associated with alzheimer's disease |
| CN115245515A (zh) * | 2021-04-27 | 2022-10-28 | 杭州剂泰医药科技有限责任公司 | 一种组合物的医药用途 |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
| IL312310A (en) * | 2021-10-27 | 2024-06-01 | Avanir Pharmaceuticals Inc | Methods for treating agitation associated with Alzheimer's disease |
| CN116459255A (zh) * | 2022-01-19 | 2023-07-21 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| CN117783322A (zh) * | 2022-12-16 | 2024-03-29 | 杭州剂泰医药科技有限责任公司 | 右美沙芬奎尼丁组合物的hplc分析方法 |
| KR20250120917A (ko) | 2024-02-02 | 2025-08-11 | 단국대학교 천안캠퍼스 산학협력단 | 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물 |
| KR20250129211A (ko) | 2024-02-22 | 2025-08-29 | 단국대학교 천안캠퍼스 산학협력단 | 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| TW264473B (https=) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
| JP4097285B2 (ja) * | 1994-09-22 | 2008-06-11 | リチャード・アラン・スミス | 種々の頑固な疾患の治療のための医薬の製造に有用な組成物 |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| EP1032377B1 (en) | 1997-11-21 | 2010-11-17 | Purdue Neuroscience Company | Substituted 2-aminoacetamides and the use thereof |
| BR9909146A (pt) | 1998-03-26 | 2000-12-05 | Shionogi & Co | Derivados de indol apresentando uma atividade antiviral |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| EP1986639A4 (en) * | 2006-02-03 | 2010-04-28 | Avanir Pharmaceuticals | PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES |
| WO2007103474A2 (en) * | 2006-03-07 | 2007-09-13 | University Of Florida Research Foundation, Inc. | Drug adherence monitoring system |
| WO2008097924A2 (en) * | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| EP2357183B1 (en) * | 2007-05-01 | 2015-07-01 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| MX370608B (es) * | 2007-05-01 | 2019-12-18 | Concert Pharmaceuticals Inc | Compuestos de morfinano. |
| DK2418211T3 (en) * | 2008-09-19 | 2016-06-27 | Concert Pharmaceuticals Inc | DEUTERATED MORPHINAN COMPOUNDS |
| US20120083487A1 (en) * | 2008-10-30 | 2012-04-05 | Amanda Thomas | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury |
| JP5647615B2 (ja) * | 2008-11-14 | 2015-01-07 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換ジオキソピペリジニルフタルイミド誘導体 |
| MY179696A (en) * | 2013-11-05 | 2020-11-11 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
-
2015
- 2015-09-14 MY MYPI2017000321A patent/MY198587A/en unknown
- 2015-09-14 EP EP15840718.9A patent/EP3193872A4/en not_active Withdrawn
- 2015-09-14 AU AU2015314710A patent/AU2015314710A1/en not_active Abandoned
- 2015-09-14 CN CN202311175974.9A patent/CN117427077A/zh active Pending
- 2015-09-14 SG SG11201701645WA patent/SG11201701645WA/en unknown
- 2015-09-14 CA CA2960031A patent/CA2960031A1/en active Pending
- 2015-09-14 TW TW109114123A patent/TW202106301A/zh unknown
- 2015-09-14 TW TW110139834A patent/TWI869633B/zh active
- 2015-09-14 JP JP2017533726A patent/JP2017531033A/ja active Pending
- 2015-09-14 MX MX2017003066A patent/MX2017003066A/es unknown
- 2015-09-14 SG SG10201901242PA patent/SG10201901242PA/en unknown
- 2015-09-14 WO PCT/US2015/049934 patent/WO2016040930A1/en not_active Ceased
- 2015-09-14 CN CN201910903770.XA patent/CN110664801A/zh active Pending
- 2015-09-14 US US15/510,498 patent/US20190111047A1/en not_active Abandoned
- 2015-09-14 EP EP21178170.3A patent/EP3932907A3/en not_active Withdrawn
- 2015-09-14 EP EP20159783.8A patent/EP3708168A3/en not_active Withdrawn
- 2015-09-14 EP EP22195837.4A patent/EP4166141A1/en not_active Withdrawn
- 2015-09-14 RU RU2017112747A patent/RU2017112747A/ru not_active Application Discontinuation
- 2015-09-14 TW TW104130311A patent/TW201613591A/zh unknown
- 2015-09-14 KR KR1020177009991A patent/KR20170052684A/ko not_active Ceased
- 2015-09-14 CN CN201580049454.0A patent/CN107072990A/zh active Pending
-
2017
- 2017-02-26 IL IL250786A patent/IL250786A0/en unknown
- 2017-03-08 MX MX2021010696A patent/MX2021010696A/es unknown
- 2017-03-08 MX MX2022008181A patent/MX2022008181A/es unknown
- 2017-03-09 PH PH12017500444A patent/PH12017500444A1/en unknown
-
2019
- 2019-10-08 US US16/596,236 patent/US20200289499A1/en not_active Abandoned
- 2019-11-06 JP JP2019201410A patent/JP2020019818A/ja not_active Withdrawn
-
2020
- 2020-05-18 IL IL274742A patent/IL274742A/en unknown
- 2020-12-15 AU AU2020289733A patent/AU2020289733A1/en not_active Abandoned
-
2021
- 2021-03-08 JP JP2021036318A patent/JP7360409B2/ja active Active
-
2022
- 2022-12-06 AU AU2022283671A patent/AU2022283671B2/en not_active Expired - Fee Related
-
2023
- 2023-04-24 US US18/305,589 patent/US20240082237A1/en not_active Abandoned
- 2023-06-12 JP JP2023096152A patent/JP2023105265A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021080300A5 (https=) | ||
| Ilias et al. | Pain control after hysterectomy: an observer‐blind, randomised trial of lornoxicam versus tramadol | |
| JP2017531033A5 (https=) | ||
| ZA200200852B (en) | Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine. | |
| JP2023143940A5 (https=) | ||
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| Essig | Newer sedative drugs that can cause states of intoxication and dependence of barbiturate type | |
| ES2237842T3 (es) | Uso de los derivados de la alcanoil carnitina en el tratamiento de los trastornos de deficit de atencion con hiperactividad. | |
| JP2010510973A (ja) | 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用 | |
| NZ529613A (en) | Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG | |
| JP2008100924A (ja) | 総合感冒薬組み合わせ製剤 | |
| Hays et al. | Using gabapentin to treat neuropathic pain | |
| US20090306204A1 (en) | Pharmaceutical Composition Comprising Cyclobenzaprine and Aceclofenac in Association | |
| US20240342160A1 (en) | Valbenazine for use in the treatment of dyskinesia due to cerebral palsy | |
| JP6926192B2 (ja) | Ｎ，ｎ−ビス−２−メルカプトエチルイソフタルアミドの新規用途 | |
| Kramer et al. | Pharmacology of outpatient anesthesia medications | |
| Khan et al. | Diphenhydramine: a review of its clinical applications and potential adverse effect profile | |
| MXPA00011035A (es) | Tratamiento de combinacion para la depresion y ansiedad. | |
| da Costa et al. | Uso de psicofármacos no tratamento da fibromialgia: uma revisão sistemática | |
| RU2719376C1 (ru) | Лекарственное средство седативного и миорелаксантного действия | |
| ES2320788T3 (es) | Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. | |
| US4609656A (en) | Medical agent for improving and treating mental symptoms induced by cerebral disturbances | |
| Capparelli | Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine | |
| WO2026052975A1 (en) | Treatments for pathological repetitive behaviours | |
| RU2008135027A (ru) | Лекарственные препараты для лечения депрессии, состояния тревоги и нейродегенеративных расстройств |